135 related articles for article (PubMed ID: 17638898)
1. Targeted cancer gene therapy using a hypoxia inducible factor dependent oncolytic adenovirus armed with interleukin-4.
Post DE; Sandberg EM; Kyle MM; Devi NS; Brat DJ; Xu Z; Tighiouart M; Van Meir EG
Cancer Res; 2007 Jul; 67(14):6872-81. PubMed ID: 17638898
[TBL] [Abstract][Full Text] [Related]
2. Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice.
Kottke T; Hall G; Pulido J; Diaz RM; Thompson J; Chong H; Selby P; Coffey M; Pandha H; Chester J; Melcher A; Harrington K; Vile R
J Clin Invest; 2010 May; 120(5):1551-60. PubMed ID: 20364090
[TBL] [Abstract][Full Text] [Related]
3. Hypoxia-targeting bacteria in cancer therapy.
Staedtke V; Sun N; Bai R
Semin Cancer Biol; 2024 May; 100():39-48. PubMed ID: 38554791
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic Adenoviruses Armed with Tumor Necrosis Factor Alpha and Interleukin-2 Enable Successful Adoptive Cell Therapy.
Havunen R; Siurala M; Sorsa S; Grönberg-Vähä-Koskela S; Behr M; Tähtinen S; Santos JM; Karell P; Rusanen J; Nettelbeck DM; Ehrhardt A; Kanerva A; Hemminki A
Mol Ther Oncolytics; 2017 Mar; 4():77-86. PubMed ID: 28345026
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic virotherapy evolved into the fourth generation as tumor immunotherapy.
Wang X; Shen Y; Wan X; Hu X; Cai WQ; Wu Z; Xin Q; Liu X; Gui J; Xin HY; Xin HW
J Transl Med; 2023 Jul; 21(1):500. PubMed ID: 37491263
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic virotherapy: basic principles, recent advances and future directions.
Lin D; Shen Y; Liang T
Signal Transduct Target Ther; 2023 Apr; 8(1):156. PubMed ID: 37041165
[TBL] [Abstract][Full Text] [Related]
7. Controlling Cell Trafficking: Addressing Failures in CAR T and NK Cell Therapy of Solid Tumours.
White LG; Goy HE; Rose AJ; McLellan AD
Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205725
[TBL] [Abstract][Full Text] [Related]
8. The Evolution and Future of Targeted Cancer Therapy: From Nanoparticles, Oncolytic Viruses, and Oncolytic Bacteria to the Treatment of Solid Tumors.
Pierce KM; Miklavcic WR; Cook KP; Hennen MS; Bayles KW; Hollingsworth MA; Brooks AE; Pullan JE; Dailey KM
Nanomaterials (Basel); 2021 Nov; 11(11):. PubMed ID: 34835785
[TBL] [Abstract][Full Text] [Related]
9. Conditioned CAR-T cells by hypoxia-inducible transcription amplification (HiTA) system significantly enhances systemic safety and retains antitumor efficacy.
He H; Liao Q; Zhao C; Zhu C; Feng M; Liu Z; Jiang L; Zhang L; Ding X; Yuan M; Zhang X; Xu J
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34615704
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic Viruses for Malignant Glioma: On the Verge of Success?
Suryawanshi YR; Schulze AJ
Viruses; 2021 Jul; 13(7):. PubMed ID: 34372501
[TBL] [Abstract][Full Text] [Related]
11. Strategies to Develop Potent Oncolytic Viruses and Enhance Their Therapeutic Efficacy.
Moaven O; Mangieri CW; Stauffer JA; Anastasiadis PZ; Borad MJ
JCO Precis Oncol; 2021; 5():. PubMed ID: 34250395
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic Viruses in Combination Therapeutic Approaches with Epigenetic Modulators: Past, Present, and Future Perspectives.
Chianese A; Santella B; Ambrosino A; Stelitano D; Rinaldi L; Galdiero M; Zannella C; Franci G
Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34199429
[TBL] [Abstract][Full Text] [Related]
13. Innovative and Promising Strategies to Enhance Effectiveness of Immunotherapy for CNS Tumors: Where Are We?
Quintarelli C; Camera A; Ciccone R; Alessi I; Del Bufalo F; Carai A; Del Baldo G; Mastronuzzi A; De Angelis B
Front Immunol; 2021; 12():634031. PubMed ID: 34163465
[TBL] [Abstract][Full Text] [Related]
14. Combination therapy with CAR T cells and oncolytic viruses: a new era in cancer immunotherapy.
Rezaei R; Esmaeili Gouvarchin Ghaleh H; Farzanehpour M; Dorostkar R; Ranjbar R; Bolandian M; Mirzaei Nodooshan M; Ghorbani Alvanegh A
Cancer Gene Ther; 2022 Jun; 29(6):647-660. PubMed ID: 34158626
[TBL] [Abstract][Full Text] [Related]
15. Personalizing Oncolytic Virotherapy for Glioblastoma: In Search of Biomarkers for Response.
Stavrakaki E; Dirven CMF; Lamfers MLM
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33557101
[TBL] [Abstract][Full Text] [Related]
16. Oncolytic Adenovirus in Cancer Immunotherapy.
Peter M; Kühnel F
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33202717
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of a novel double-controlled oncolytic adenovirus driven by the Ki67 core promoter and armed with IL-15 against glioblastoma cells.
Zhang Q; Zhang J; Tian Y; Zhu G; Liu S; Liu F
Cell Biosci; 2020; 10():124. PubMed ID: 33133514
[TBL] [Abstract][Full Text] [Related]
18. Advances and potential pitfalls of oncolytic viruses expressing immunomodulatory transgene therapy for malignant gliomas.
Zhang Q; Liu F
Cell Death Dis; 2020 Jun; 11(6):485. PubMed ID: 32587256
[TBL] [Abstract][Full Text] [Related]
19. Oncolytic Adenoviruses: Strategies for Improved Targeting and Specificity.
Hajeri PB; Sharma NS; Yamamoto M
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32526919
[TBL] [Abstract][Full Text] [Related]
20. Prolonged Persistence of Chimeric Antigen Receptor (CAR) T Cell in Adoptive Cancer Immunotherapy: Challenges and Ways Forward.
Jafarzadeh L; Masoumi E; Fallah-Mehrjardi K; Mirzaei HR; Hadjati J
Front Immunol; 2020; 11():702. PubMed ID: 32391013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
